Summary
The antihypertensive efficacy and acceptability of 3 doses of rilmenidine (0.5, 1 and 2 mg, once daily) and a placebo over a 4 week period have been compared in a randomised, double-blind, parallel-group trial in 60 mild to moderate hypertensive patients. Six patients dropped out: 4 in the 2 mg-group and one in the 1 mg-group because of adverse events, and one in the placebo group for personal reason. The blood pressure was significantly decreased after the 1 and 2 mg doses with the maximum antihypertensive effect already being obtained after 1 mg. A significant dose-effect relationship was shown for supine systolic blood pressure (P=0.05) but not for the supine diastolic blood pressure.
The most beneficial efficacy/acceptability ratio was achieved at the dose of 1 mg once daily, which demonstrated the maximum antihypertensive effect associated with a low incidence of adverse events.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gomez RE, Ernsberger P, Feinland G, Reis D (1991) Rilmenidine lowers arterial pressure via imidazole receptors in brainstem C1 area. Eur J Pharmacol 195: 181–191
Dollery CT, Davies DS, Duchier J, Pannier B, Safar ME (1988) Dose and concentration-effect relations for rilmenidine. Am J Cardiol 61: 60D-66D
Ostermann G, Brisgand B, Schmitt J, Fillastre JP (1988) Efficacy and acceptability of rilmenidine for mild to moderate systemic hypertension. Am J Cardiol 61: 76D-80D
Chalmers J, Wing L, Taylors S (1990) Analysis of time trends, individual subject responses and background variation in crossover factorial studies with antihypertensive drugs. J Hypertens 8 [Suppl 4]: S27-S35
Fillastre JP, Letac B, Galinier F, Le Bihan G, Schwartz J (1988) A multicenter double-blind comparative study of rilmenidine and clonidine in 333 hypertensive patients. Am J Cardiol 61: 81D-85D
Galley P, Manciet G, Hessel JL, Michel JP (1988) Antihypertensive efficacy and acceptability of rilmenidine in elderly hypertensive patients. Am J Cardiol 61: 86D-90D
United Kingdom Working Party on Rilmenidine (1990) Rilmenidine in mild to moderate essential hypertension. A doubleblind, randomised, parallel-group, multicenter comparison with methyldopa in 157 patients. Current Therap Res 47: 194–211
Dallochio M, Gosse P, Fillastre JP, Grollier G, Morand P, Drici M, Corcoran C (1991) La rilmenidine, un nouvel antihypertenseur dans le traitement de première intention de l'hypertension artérielle essentielle. Presse Med 20: 1265–1271
Fiorentini C, Guillet C, Guazzi M (1989) A multicentre coubleblind trial comparing rilmenidine 1 mg and hydrochlorothiazide 25 mg in 244 patients. Arch Mal Coeur 82: 39–46
Bousquet P, Feldman J, Schwartz J (1984) Central cardiovascular effect of alpha-adrenergic drug: differences between catecholamines and imidazoles. J Pharmacol Exp Ther 230: 232–236
Coupry I, Lachaud V, Podevin RA, Koenig E, Parini A (1989) Different affinities of α2 agonist for imidazoline and α2 adrenergic receptors. Am J Hypertens, 2: 468–470
Langin D, Paris H, Dauzats M, Lafontan M (1990) Discrimination between alpha 2-adrenoceptors and [3H]idazoxan — labelled non-adrenergic sites in rabbit white fat cells. Eur J Pharmacol, 188: 261–272
Lachaud-Pettiti V, Podevin RA, Chretien Y, Parini A (1991) Imidazoline-guanidinium and alpha 2 adrenergic binding sites in basolateral membranes from human kidney. Eur J Pharmacol, 206: 23–31
Tesson F, Prip-Buus C, Lemoine A, Pegorier JP, Parini A (1991) Subcellular distribution of imidazoline-guanidinium-receptive sites in human and rabbit liver. J Biol Chem 266: 155–160
Bricca G, Dontenwill M, Molines A, Feldman J, Tibirica E, Belcourt A, Bousquet P (1989) Rilmenidine selectivity for imidazoline receptors in human brain. Eur J Pharmacol 163: 373–377
Van Zwieten PA, Thoulen JMC, Jonkman FAM, Wilffert B, De Jonge A, Timmermans PBMWM (1986) Central and peripheral effects of S3341 [(N-dicyclopropylmethyl)-amino-2-oxazoline] in animal models. Arch Int Pharmacodyn Ther, 279: 130–149
Beau B, Mahieux F, Paraire M, Laurin S, Brisgand B, Vitou P (1988) Efficacy and safety of rilmenidine for arterial hypertension. Am J Cardiol 61: 95D-102D
Gould BA, Mann S, Davies AB, Altman DG, Raftery EB (1981) Does placebo lower blood pressure? Lancet II: 1377–1381
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Luccioni, R., Lambert, M., Ambrosi, P. et al. Dose-effect relationship of rilmenidine after chronic administration. Eur J Clin Pharmacol 45, 157–160 (1993). https://doi.org/10.1007/BF00315498
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315498